Onkologie. 2008:2(4):219-222

SURGICAL TREATMENT FOR LIVER CANCER

Vladislav Třeška
Chirurgická klinika FN Plzeň

Recent years have seen a significant advancement in liver surgery, particularly due to new technical possibilities. There has been a marked decrease in morbidity following liver resection which is now less than 3 %. Currently, the five-year survival rate of patients after primary liver resection ranges from 25 to 40 % and about 20 % of patients survive for ten years. At present, the preferred treatment of choice is surgical liver resection (by open or laparoscopic approach), however, the introduction of new combined oncological approaches using biological therapy has resulted in a major improvement in long-term outcomes for both primary and secondary liver tumours. The second treatment of choice is thermal ablation, today mainly represented by radiofrequency and microwave ablation. The long-term outcomes of these methods are less favourable, especially when liver metastases are present, than those of conventional surgical treatment. Only 15–20 % of patients with liver tumours are operable. An increased operability of these patients may be achieved in several ways: by promotion of hepatic tissue regeneration using portal vein embolization of the portal branch at the side of the tumour, or by chemotherapeutic down-staging; both of these are so-called staged procedures. Whether to use simultaneous or consecutive procedures in synchronous metastases of colorectal cancer remains to be answered. The simultaneous procedure is beneficial in simple colorectal resections in which hepatectomy is performed first in order to protect the bowel anastomosis during transient portal hypertension due to closure of the portal vein at the time of liver resection.

Keywords: Key words: liver resection, thermoablative procedures, laparoscopy, combined oncological therapy, portal vein embolization, down-staging, staged procedures, simultaneous procedures.

Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Třeška V. SURGICAL TREATMENT FOR LIVER CANCER. Onkologie. 2008;2(4):219-222.
Download citation

References

  1. Paschos K, Bird N. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. Hippokratia. 12, 2008; 132-138. Go to PubMed...
  2. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: Current perspectives. Cancer Control, 13, 2006; 1: 32-41. Go to original source... Go to PubMed...
  3. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur. J. Cancer, 38, 2002; 7: 1023-1033. Go to original source... Go to PubMed...
  4. Kockerling F, Schwartz SI. Liver Surgery. 1. vyd., Heidelberg, J. A. Barth, 2001; 51-65.
  5. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235, 2002; 6: 759-766. Go to original source... Go to PubMed...
  6. Nguyen KT, Gamblin TC. Laparoscopic liver resection for cancer. Future Oncol. 4, 2008; 661-670. Go to original source... Go to PubMed...
  7. Skalický T, Třeška V, Šnajdauf J. Chirurgie jater. 1. vyd., Praha, Maxdorf-Jessenius 2004; 86-110.
  8. Třeška V. Technika jaterních resekcí. Rozhl. Chir., 82, 2003; 8: 397-402.
  9. Konopke R, Kersting S, Makowiec F, Gassman P, Kuhlisch E, Saeger HD. Resection of colorectal liver metastases: is a resection margin of 3 mm enough? A multicenter analysis of the GAST Study Group. World j Surg, 32, 2008; 2047-2056. Go to original source... Go to PubMed...
  10. Jonas S, Thelen A, Benckert C, et al. Extended resections of liver metastases from colorectal cancer. World J Surg, 31, 2007; 51-521. Go to original source... Go to PubMed...
  11. Scheingraber S, Richter S, Igna D, et al. Indocyanine green disappearance rate is the most useful marker for liver resection. Hepatogastroenterology, 55, 2008; 1394-1399. Go to PubMed...
  12. Karoui M, Koubaa W, Delbaldo C, et al. Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol. 11, 2008; 132-138. Go to original source... Go to PubMed...
  13. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 10, 2008; 1623-1641.
  14. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenetrolog., 2, 2003; 9: 193-200. Go to original source... Go to PubMed...
  15. Vyhnánek F, Denemark L, Duchač V, Škrábalová D. Kdy indikovat resekci jater u metastáz? Rozhl. Chir. 82, 2003; 11: 570-576.
  16. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged chemotherapy: a model to predict long-term survival. Ann. Surg. 240, 2004; 4: 644-657. Go to original source... Go to PubMed...
  17. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 243, 2006; 1-7. Go to original source... Go to PubMed...
  18. Strnad R, Ryska M, Bělina F, Langer D, Novotný J, Ludvíková M. Predikce léčebné odpovědi po lokoregionální chemoterapii u nemocných po resekcích jater pro jaterní metastázy kolorektálního karcinomu. Rozhl Chir, 2006; 85, 124-128. Go to PubMed...
  19. Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol, 26, 2008; 3672-3680. Go to original source... Go to PubMed...
  20. Ferrara N, et al. Discovery and development of bevacizumab. An anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 2004; 391-400. Go to original source... Go to PubMed...
  21. Hurwitz H, et al. Bevacizumab plus innotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 350, 2004; 2335-2342. Go to original source... Go to PubMed...
  22. Curley SA, Izzo F, Abdalla E, et al. Surgical treatment of colorectal metastasis. Cancer Metastasis Rev. 23, 2004; 1-2, 165-182. Go to original source... Go to PubMed...
  23. Skalický T, Třeška V. Radiofrekvenční ablace jaterních nádorů. 1.vyd., Praha, Maxdorf-Jessenius, 2006; 21-36.
  24. Wong SL. Edwards MJ, Chao C. Radiofrequency ablation for unresectable hepatic tumors. Am J Surg, 182, 2001; 552-557. Go to original source... Go to PubMed...
  25. Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 8, 2008; 345-349. Go to original source... Go to PubMed...
  26. Hillings JG, Wille-Jorgensen. P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer - A systematic review. Colorectal Dis., 1, 2008; 1340-1346. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.